NCT01853852
A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
Phase: Phase 1
Role: Lead Sponsor
Start: Sep 30, 2011
Completion: Dec 31, 2011